New drug combo targets Hard-to-Treat cancers with specific gene deletion

NCT ID NCT07699757

First seen Jul 13, 2026 · Last updated Jul 15, 2026 · Updated 2 times

Summary

This study tests an experimental drug called HSK41959, taken as a tablet, in combination with standard cancer treatments for people with advanced solid tumors that lack a gene called MTAP. The trial includes patients with non-small cell lung cancer, pancreatic cancer, and other advanced solid tumors. The main goals are to check the safety and tolerability of the combination and to get an early look at how well it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
HSK41959
What this could lead to
If successful, this could point toward a new treatment option for people with certain hard-to-treat cancers that have an MTAP gene deletion.
What could go wrong
This is an early-phase trial, so the drug may not work as hoped or could cause unexpected side effects. Results are preliminary and need confirmation in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.